ISPOR 4th Asia-Pacific Conference: Educational Symposia
 
Join ISPOR  | Sign up for mailing List  | Follow Us: LinkedIn Twitter Facebook YouTube
Sunday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

SUNDAY, 5 SEPTEMBER 2010
5:15PM - 6:15PM

Meeting Payer and HTA Requirements: The Value of New Innovative Biologic Therapy in the Treatment of WAMD

Grand Ballroom B

Around the world, pricing concerns and need for evidence of product value have created additional hurdles to market access beyond registration. Payers and agencies responsible for health technology assessment have requested additional economic and humanistic evidence to assess a products overall value and place in therapy. Neovascular, or ‘wet’ age-related macular degeneration is a degenerative disorder of the retinal macula associated with severe and irreversible problems. It has a high economic burden and increasing prevalence. While a new innovative biologic therapy may offer significant clinical benefits, it also presents new challenges from a market access perspective for healthcare systems in Asia-Pacific. This symposium will offer insights into how to evaluate the value of innovative biologic therapy in the management of neovascular AMD through review and discussion of current literature and status on this topic.

Moderator:  Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

CONSIDERATIONS FOR THE ECONOMIC EVALUATION OF NEW BIOLOGIC THERAPIES
Speaker: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

SPOTLIGHT ON NEOVASCULAR AMD: DISEASE BURDEN AND THERAPEUTIC OPTIONS
Speaker: TBD

ANTI-VEGF THERAPY IN NEOVASCULAR AMD: COST-EFFECTIVENESS EVALUATION AND REVIEW OF EVIDENCE
Speaker: Alan Haycox PhD, Professor, University of Liverpool, Liverpool, UK

Sponsored by Novartis
Novartis Logo


Sunday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

SUNDAY, 5 SEPTEMBER 2010
6:30PM - 7:30PM

What Is The "Right" Cost Per QALY For Innovative And Life-Saving Oncology Or End-Of-Life Therapies?

Grand Ballroom B

The cost effectiveness criteria of £30 000 (or US$50,000) per QALY has long been used by NICE and other regulatory agencies around the global to determine the drug coverage benefit levels for their respective insurance plans. Not only has the evaluation criteria not been inflation indexed since its introduction; In the past few years, the new innovative biological therapies, cancer therapies, and other end of life therapies posed significant challenges to this old threshold. The significant social and political pressures from population demanding new and better therapies has caused NICE to revise its guidance upward on the cost effectiveness criteria for end of life therapies. The wiliness to pay literature also suggest that public might be willing to pay up to £70 000 per QALY. In this symposium, we will explore the rational and practical implication of NICE revised guideline and discuss what is the “right” cost effectiveness criteria for technology adaptation and should there be a higher threshold for cancer drugs, biological, and other end of life care therapies.

Moderator: Shanlian Hu MD, MSc, Professor, School of Public Health, Fudan University, and Director, Center for Health Development Research, Shanghai Bureau of Health, Shanghai, China

NICE END OF LIFE GUIDELINE AND ITS IMPLICATIONS
Speaker:Kenneth KC Lee JP, BSc(Pharm), MPhil, PhD, Professor of Pharmacy and Head of Pharmacy Program, School of Medicine and Health Sciences, Monash University, Kuala Lumpur, Malaysia

Global experience on ICER criteria application
Speaker:Boxiong Tang PhD, Outcomes Research, Emerging Markets, Pfizer Inc, New York, NY, USA

Sponsored by Pfizer
Pfizer Logo


Sunday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

SUNDAY, 5 SEPTEMBER 2010
7:45PM - 8:45PM

Value-based Pricing and Patient Access to Oncology Drugs in Asia

Grand Ballroom B

Oncology treatment is one of the most challenging areas for policy makers to make reimbursement decisions. Policy markers increasingly strive for value-based purchasing - the best value for their purchasing power. However, this challenging environment has led to innovative drugs being unable to reach the patients for which they were designed to treat due to lack of governmental reimbursement. What is value-based pricing? This symposium will help the audience to:

    1. Understand Asia stakeholders needs;
    2. Gain insights on stakeholders and key value drivers in Asia for oncology reimbursement;
    3. Understand how the drug impacts each stakeholder when compared with competitors in Asia;
    4. Quantify value and ultimately translate value into price, and how to adjust to Asia local environment;
    5. Understand what main hurdles that pharmaceutical companies are facing for implementing value-based pricing in Asia

Moderator: Gordon G. Liu PhD, Professor of Economics, and Executive Director, The Health Economics and Management Institute, Peking University Guanghua School of Management, Beijing, China

Oncology Drug Market Access in Singapore, Challenges and Opportunity
Gilberto de Lima Lopes Jr., MD, Internal Medicine (ABIM), Medical Oncology (ABIM) Consultant in Medical Oncology, Assistant Director for Clinical Research , Johns Hopkins Singapore International Medical Centre, Singapore  

Oncology Drug Pricing in Thailand, Current and Future
Netnapis Suchonwanich MS, Director, Bureau Fund Administration of National Health Security Office, Bangkok, Thailand

Oncology Drug Access in Asia Pacific
Christopher-Paul Milnes PhD, Tufts Centre for Study of Drug Development, MA, USA

Sponsored by Bayer (South East Asia) Pte Ltd


Bayer HealthCare Logo

Monday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

MONDAY, 6 SEPTEMBER 2010
12:45PM - 1:45PM

Simultaneous Thai/English translation provided English presentations translated to Thai, Korean & Chinese

HTA CHALLENGES IN ASIA: PROGRESS THROUGH PARTNERSHIPS

Grand Ballroom B

Health technology assessment (HTA) partnerships between health technology assessors and developers and patients and/or caregivers are an approach that can help to manage treatment outcomes uncertainty and improve HTA methods. A panel of international experts knowledgeable of well established HTA systems will a) discuss progress in the engagement of industry and patient groups; b) identify positive changes emerging from such partnerships and the challenges experienced; and c) outline the importance of social and ethical considerations, which are often overlooked in the development of HTA systems.

Moderator: Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

ENGAGING WITH STAKEHOLDERS IN THE HTA PROCESS: SOME OBSERVATIONS OF AUSTRALIAN EXPERIENCE
Speaker: Rosalie Viney PhD, Associate Professor of Health Economics and Deputy Director, Centre for Health Economics Research and Evaluation, Faculty of Business, University of Technology, Sydney, Australia

THE NICE WAY OF INVOLVING STAKEHOLDERS
Speaker: Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

STAKEHOLDERS PARTICIPATION IN THE HTA PROCESS: SOUTH KOREA
Speaker: Bong-Min Yang PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

Sponsored by Eli Lilly
Eli Lilly Logo


Monday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

MONDAY, 6 SEPTEMBER 2010
2:00PM - 3:00PM

Opportunities and Challenges in the Emerging Markets of Asia: Implications for Pricing, Market Access and Health Economics and Outcomes Research

Grand Ballroom B

This symposium will provide some perspectives and insights on some of the emerging markets in Asia. These markets present both challenges and opportunities for health care improvement as well as the development and deployment of medical services and technologies. Some of the shared issues of these markets include: extending basic health care to large underserved populations, managing escalating costs or health care (which will of course increase as health care services are extended to larger populations), spurring innovation in medical technologies and health care delivery, and improving health care quality across all population segments. As local manufacturers and “multinationals” try to engage decision-makers in these markets, traditional business models may not apply. The implications this situation has for pricing, market access and Health Economics and Outcomes Research (HEOR) will be addressed by the speakers. This symposium should be of value to anyone within the ISPOR audience with a regional role in Asia and/or an interest in the emerging markets of Asia.

Moderator: Jonothan Tierce C.Phil , General Manager and Center of Excellence Leader, Global Health Economics & Outcomes Research, IMS Health, Falls Church, VA USA

2:00PM - 2:05PM  Introduction
Jonothan Tierce C.Phil, General Manager and Center of Excellence Leader, Global Health Economics & Outcomes Research, IMS Health, Falls Church, VA USA

2:05PM - 2:20PM  ACESS FOR PATIENTS, EXPENDITURE MANAGEMENT, INDUSTRIAL POLICY: LESSONS TO BE LEARNED FROM EUROPE IN EMERGING ASIA-PACIFIC MARKETS
Annie Chicoye PhD, Associate Professor, ESSEC-Santé Business School, Paris-Singapore

2:20PM - 2:35PM  THE CHALLENGING PRICING AND MARKET ACCESS LANDSCAPE IN ASIA-PACIFIC - WHAT DOES THIS MEAN FOR YOU?
Mandy Chui MBA, Regional Practice Leader, Pricing & Market Access for Asia-Pacific, IMS Health Asia, Beijing, China

2:35PM - 2:50PM  WAYS TO ADRESS PRICING AND MARKET ACCESS CHALLENGES IN ASIA-PACIFIC
Abdulkadir Keskinaslan MD, MBA, MPH, Market Pricing Director Asia, Novartis Pharma AG, Basel, Switzerland

2:50PM - 3:00PM QUESTIONS AND ANSWERS

Sponsored by IMS
IMS Logo


Tuesday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

TUESDAY, 7 SEPTEMBER 2010
7:30AM - 8:30AM

Estimating the Humanistic and Cost Burden of Chronic Obstructive Pulmonary Disease (COPD)

Grand Ballroom B

COPD is a global health concern, and is a major cause of chronic morbidity and mortality worldwide. The World Health Organization (WHO) estimated the global prevalence of chronic obstructive pulmonary disease (COPD) in 2000 at 210 million. Overall COPD prevalence ranges from about 5% to about 11% of all adults, but a surprising proportion of young adults (20–44 years old) have evidence of airway obstruction. The WHO estimated that COPD was responsible for 3 million deaths worldwide in 2000, and will become the 4th leading cause of death by 2030.

When compared to the developed Western countries, the COPD burden in the Asia-Pacific Region is higher in terms of the number of deaths; years spent living with disability and years of life lost. Given the increasing burden of COPD and high prevalence of the disease in the Asia-Pacific region, there is an urgent need for a multi-disciplinary approach in improving disease awareness, in championing health policies that reduce disease burden and in the wider use of effective management in the treatment and management of COPD.

7:30AM - 7:35AM WELCOME AND INTRODUCTION
Gordon Liu PhD, Professor and Chair, Dept of Health Economics and Management, Peking University Guanghua School of Management, Beijing, China

7:35AM - 7:50AM COPD DISEASE BURDEN: ECONOMIC, HUMANISTIC
Gordon Liu PhD, Professor and Chair, Dept of Health Economics and Management, Peking University Guanghua School of Management, Beijing, China
 
7:50AM - 8:05AM COPD UNCOVERED: EVALUATION OF WIDER COSTS OF COPD
Mike Baldwin, Novartis Horsham Research Centre, Horsham, United Kingdom

8:05AM - 8:20AM EVALUATING AN OPTIMAL DISEASE MANAGEMENT PROGRAM
Isao Kamae MD, DrPH, Professor, Graduate School of Health Management, Keio University, Tokyo, Japan

8:20AM - 8:30AM  QUESTION & ANSWER

Sponsored by Novartis
Novartis Logo


Tuesday Educational Symposium during the ISPOR 4th Asia-Pacific Conference

TUESDAY, 7 SEPTEMBER 2010
12:15PM - 1:15PM

Market Access to Biologics in Asia Pacific

Grand Ballroom B

Biologics have become a main treatment option for various diseases in the West; however, its use in the Asia-Pacific region is limited, even in economically advanced Japan, Singapore, South Korea, and Taiwan. The objectives of this symposium are to: 1) characterize the trends and patterns of use of biologics in this region, 2) to identify the main barriers and drivers of access to biologics, 3) to discuss the clinical benefits and costs of biologics, and 4) to explore the implications of health policies on reimbursement and use of biologics in the Asia-Pacific region.

Moderator: Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA

12:15PM - 12:20PM  WELCOME & INTRODUCTION
Speaker: Mingliang Zhang PhD, Senior Director, Worldwide Market Access, Global Strategic Marketing and Market Access, Johnson and Johnson Pharmaceutical Services, Horsham, PA, USA

12:20PM - 12:35PM THE EXPERIENCE ON THE CONTROL AND MANAGEMENT OF BIOLOGICS
Speaker: Haijun Zhou, Professor, Honorary President of NICPBP (National Institute for the Control of Pharmaceutical and Biological Products), SFDA (State Food and Drug Administration), Beijing, China

12:35PM - 12:50PM THE CLINICAL VALUE AND COST OF BIOLOGICS
Speaker: Zhuoli Zhang MD, Professor, First Affiliated Hospital of Peking University, Beijing, China

12:50PM - 1:05PM THE TREND TO UTILIZE BIOLOGICS AND ACCESS BARRIERS
Speaker: Wen Chen PhD, Professor, Center for Pharmacoeconomic Research and Evaluation, Fudan University, Shanghai, China

1:05PM - 1:15PM QUESTION & ANSWER

Sponsored by Johnson & Johnson Pharmaceutical Services
Johnson & Johnson Logo


4th Asia-Pacific Conference Main Page

 

Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2014 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.